Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer

• Status: Completed
• Trial end date: 2014-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the maximal tolerated dose (MTD) and overall safety of sunitinib when administered in combination with S-1 and Cisplatin in patients with advanced/metastatic gastric cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Cisplatin; Sunitinib

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed diagnosis of gastric cancer

• Chemonaive patients

• Adequate organ function

Exclusion Criteria:

• Patients who meet the contra-indications of S-1 and Cisplatin.

• Prior chemotherapy failure patients